HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Erythropoietin in multiple myeloma].

Abstract
In a 59-year-old man with multiple myeloma (kappa-light chain paraproteinaemia) in stage IIIB, bone marrow infiltration with atypical plasma cells was reduced by five cytostatic treatment courses with vincristine, melphalan, cyclophosphamide and prednisone (VMCP protocol), but anaemia requiring blood transfusion persisted (haemoglobin concentration 5.3 g/dl). Even administration of interferon alpha-2b (5 million units s.c. every other day) failed to alter this. Only a combination of interferon and erythropoietin (150 U/kg i.v. every other day) achieved lasting regression of the anaemia (haemoglobin concentration up to 14 g/dl). In four other anaemic patients with multiple myeloma, stage III, treated according to the VMCP protocol but without additional interferon, erythropoietin did not improve erythropoiesis.
AuthorsM Pecherstorfer, F Schmoranzer, M Vesely, A Fortelny, G Baumgartner
JournalDeutsche medizinische Wochenschrift (1946) (Dtsch Med Wochenschr) Vol. 115 Issue 28-29 Pg. 1096-9 (Jul 13 1990) ISSN: 0012-0472 [Print] Germany
Vernacular TitleErythropoietin beim multiplen Myelom.
PMID2373040 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Interferon alpha-2
  • Interferon-alpha
  • Recombinant Proteins
  • Erythropoietin
  • Vincristine
  • Cyclophosphamide
  • Melphalan
  • Prednisone
Topics
  • Aged
  • Aged, 80 and over
  • Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
  • Bone Marrow (pathology)
  • Cyclophosphamide (administration & dosage)
  • Erythropoiesis
  • Erythropoietin (administration & dosage, therapeutic use)
  • Female
  • Humans
  • Interferon alpha-2
  • Interferon-alpha (administration & dosage)
  • Male
  • Melphalan (administration & dosage)
  • Middle Aged
  • Multiple Myeloma (drug therapy, pathology)
  • Prednisone (administration & dosage)
  • Recombinant Proteins
  • Vincristine (administration & dosage)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: